Drug intelligence / Profile preview

ISH0888

Development stage: Unknown
Lead developer: SUNHO BioPharmaceutical
Modality: Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics

Overview

ISH0888 is an anti-inflammatory bispecific antibody (bsAb) developed by Guangdong Sunho (Sunho Biopharmaceutical) for the treatment of inflammatory bowel disease (IBD). The therapeutic is engineered using Sunho's proprietary bispecific antibody platform to simultaneously target two distinct pathways involved in intestinal inflammation. As of 2024, the specific biological targets and detailed mechanism of action remain confidential, although the asset has progressed into Phase 1 clinical development to evaluate its safety, tolerability, and preliminary efficacy in patients with IBD.

Beyond the preview

Go deeper on ISH0888.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ISH0888.

Explore the full profile